Arsenal Biosciences Closes $220 Million Series B Financing to Advance Programmable Cell Therapy Programs into Clinical Development

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Arsenal Biosciences closes $220 million series B to advance its programmable cell therapy programs for solid tumor cancers into clinical development.

Click to view original post